Shots: The approval is based on safety & efficacy data from the P-III LIBERTY program that consists of 2 studies i.e LIBERTY 1 & 2 evaluating Ryeqo in adult women […]readmore
Tags : Ryeqo
In an interview with PharmaShots, Myovant’s Juan Camilo Arjona Ferreira, MD, Chief Medical Officer of Myovant Sciences shares his views on the CHMP’s positive opinion for Ryeqo (Relugolix Combination Tablet). […]readmore